Speed ​​reading agency Rongchang Biological Vidicuzumab's new indications are included in the priority review and multiple provinces determine the implementation time of the fifth batch of centralized procurement

Policy briefing

Policy briefing

Announcement of the results of the second round of centralized drug procurement in Jiangsu Province

Announcement of the results of the second round of centralized drug procurement in Jiangsu Province

On the 10th, the Jiangsu Provincial Medical Insurance Bureau issued the "Announcement on the Second Round of Centralized Purchase of Pharmaceuticals in Jiangsu Province (8)
.

" The Alliance Office organized experts to carry out bidding and negotiation of the declared products, and the result of this purchase was planned to be selected, involving a total of 10 drugs

Tianjin, Shaanxi, and Hainan determine the implementation time of the fifth batch of centralized procurement

Tianjin, Shaanxi, and Hainan determine the implementation time of the fifth batch of centralized procurement

On the 10th, another three provinces and municipalities issued announcements to clarify the landing time of the fifth batch of centralized procurement
.

Specifically: 1.

The two departments jointly issued a document: Adapt to the normalization of national medical insurance negotiations and continue to do a good job in the negotiation of drugs

The two departments jointly issued a document: Adapt to the normalization of national medical insurance negotiations and continue to do a good job in the negotiation of drugs

On the 10th, the National Medical Insurance Administration and the National Health Commission jointly issued a notice on adapting to the normalization of national medical insurance negotiations and continuing to do a good job in the implementation of negotiated drugs
.

The notice emphasized that medical security, health and health departments at all levels must earnestly improve their political positions and enhance active coordination

Observation of Obstetrics

Observation of Obstetrics

Kangmei Pharmaceutical announces reorganization

Kangmei Pharmaceutical announces reorganization

On the 11th, Kangmei Pharmaceutical issued the "Announcement on Reorganization Progress and Risk Warning"
.

The announcement stated that Kangmei Pharmaceutical's reorganization progressed this month to receive the "Decision Letter" of Jieyang Intermediate People's Court, which recognized the composition of the company's creditors committee

Flamingo and Ionis collaborate to develop antisense oligonucleotide anticancer therapy targeting non-coding RNA

Flamingo and Ionis collaborate to develop antisense oligonucleotide anticancer therapy targeting non-coding RNA

Recently, Flamingo Therapeutics announced an agreement with Ionis Pharmaceuticals to jointly develop RNA targeted therapies to treat various forms of cancer
.

(WuXi AppTec)

iECURE and Precision team up to develop in vivo gene editing therapy and complete US$50 million in Series A financing

iECURE and Precision team up to develop in vivo gene editing therapy and complete US$50 million in Series A financing

Recently, Precision BioSciences and iECURE announced a licensing and cooperation agreement
.

According to the terms of the agreement, iECURE plans to advance Precision's PGBENE-PCSK9 drug candidates into phase 1 clinical studies, and obtain the rights to use Precision's ARCUS nuclease targeting PCSK9 to develop in vivo gene editing therapies for genetic diseases, which will initially target the liver Disease

Medicine News

Medicine News

Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released

Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released

Recently, Apellis announced the top-line results obtained in two phase 3 clinical trials, DERBY and OAKS, in the research pegcetacoplan, which targets the complement C3 protein
.

The test results showed that the OAKS test reached the primary endpoint

Phase 3 clinical trial of cell therapy for the treatment of severe complications of diabetes yields positive mid-term results

Phase 3 clinical trial of cell therapy for the treatment of severe complications of diabetes yields positive mid-term results

Recently, Ixaka announced that its ongoing autologous multi-cell therapy REX-001 has achieved positive interim results in a phase 3 clinical trial
.

In this randomized, double-blind, placebo-controlled trial, the primary endpoint is complete healing of the ulcer

Junshengtai HTD1801 officially launches clinical trials in China

Junshengtai HTD1801 officially launches clinical trials in China

On the 10th, Junshengtai announced that its HTD1801 PK bridging test in the Chinese population has completed the enrollment and administration of the first batch of subjects
.

The trial will successively enroll 24 healthy subjects, aiming to evaluate the safety, tolerability and main pharmacokinetic properties of HTD1801 in Chinese healthy subjects, as a comprehensive promotion of HTD1801 in the treatment of type 2 diabetes and diabetes in China.
The basis of clinical trials for other metabolic diseases
.
(Medicine Cube)

CRISPR-edited stem cell therapy for the treatment of acute myeloid leukemia obtains FDA fast-track qualification

CRISPR-edited stem cell therapy for the treatment of acute myeloid leukemia obtains FDA fast-track qualification

Recently, Vor Biopharma announced that the US FDA has granted its engineered hematopoietic stem cell drug candidate VOR33 fast track qualification for the treatment of acute myeloid leukemia
.
(WuXi AppTec)

Rongchang Bio-Vidicuzumab urothelial carcinoma indications included in priority review

Rongchang Bio-Vidicuzumab urothelial carcinoma indications included in priority review

On the 10th, the CDE official website showed that the second indication of Rongchang Bio-targeting HER2 antibody-conjugated drug vedicitumumab was officially included in the priority review for the treatment of previous systemic chemotherapy and HER2 expression as an immunohistochemical examination The result is 2+ or 3+ patients with locally advanced or metastatic urothelial carcinoma
.
(CDE)

Qilu Pharmaceutical and Chengdu Beteluvatinib are about to be approved

Qilu Pharmaceutical and Chengdu Beteluvatinib are about to be approved

On the 10th, Qilu Pharmaceutical and Chengdu Better's first-line targeted therapy drug lenvatinib for liver cancer both entered the approval stage and are expected to be approved in the near future
.
(NMPA)

Hisun Pharmaceutical's infliximab will be approved soon

Hisun Pharmaceutical's infliximab will be approved soon

On the 10th, the NMPA official website indicated that Hisun Pharmaceutical’s infliximab biosimilar has entered the administrative approval stage and is expected to be approved in the near future
.
Infliximab is a human-mouse chimeric monoclonal antibody developed by Johnson & Johnson/Mersk & Co.
, which specifically blocks tumor necrosis factor
.
(NMPA)

Jingfeng Pharmaceutical Subsidiary Received Notification of Approval of Bingzhishangtong Aerosol Drug Supplement Application

Jingfeng Pharmaceutical Subsidiary Received Notification of Approval of Bingzhishangtong Aerosol Drug Supplement Application

On the 12th, Jingfeng Pharmaceutical issued an announcement stating that its subsidiary Jingcheng Pharmaceutical had received the "Drug Supplementary Application Approval Notice" for Bingzhishangtong aerosol approved and issued by NMPA
.
The main function of the drug is to clear away heat, detoxify and cool blood, promote blood circulation, remove blood stasis and relieve pain
.
It can be used for traumatic injuries, blood stasis, swelling and pain, and also for superficial second-degree burns
.
(a)

Glipizide tablets, a wholly-owned subsidiary of Zhongsheng Pharmaceutical, passed the consistency evaluation of generic drugs

Glipizide tablets, a wholly-owned subsidiary of Zhongsheng Pharmaceutical, passed the consistency evaluation of generic drugs

On the 11th, Zhongsheng Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Huanan Pharmaceutical, had received the "Notice of Approval of Drug Supplement Application" approved and issued by NMPA for the treatment of type 2 diabetes
.
(a)

Junshi Biologics submits Claudin 18.
2 monoclonal antibody clinical application

Junshi Biologics submits Claudin 18.
2 monoclonal antibody clinical application

On the 10th, Junshi Bio announced that the submitted clinical trial application for JS012 injection has been accepted by NMPA for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer
.
(a)